RECURRENT WALDENSTROM MACROGLOBULINEMIA
Clinical trials for RECURRENT WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase trial is testing whether combining two drugs—nivolumab (a monoclonal antibody) and lenalidomide (a chemotherapy-like drug)—can safely and effectively treat people with non-Hodgkin or Hodgkin lymphoma that has returned or is not responding to treatment. The study …
Matched conditions: RECURRENT WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo shows promise for tough lymphoma
Disease control OngoingThis study tests adding a drug called selinexor to the standard chemotherapy RCHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced or returning ly…
Matched conditions: RECURRENT WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC